Skip to main content
. Author manuscript; available in PMC: 2020 Dec 8.
Published in final edited form as: Nat Chem Biol. 2020 Jun 8;16(9):997–1005. doi: 10.1038/s41589-020-0555-4

Extended Data Fig. 5. Effects of chronic treatment of DIO mice with a pharmacological LYPLAL1 activator.

Extended Data Fig. 5

DIO mice were treated with 12 for 28 days. (a) Body weights (left panel: n=8 for veh, n=9 for 12; right panel: n=7 for veh, 12 and 12 + C11 groups, n=8 for C11) prior to OGTT (left panel: d 11, right panel: d 8) and ITT (left panel: d 15, right panel: d 12); cumulative food intake per mouse (left panel: n=3 cages for veh and 12, right panel: n=2 cages for all groups) of vehicle and compound-treated DIO mice. (b) Indicated tissues from DIO mice were analyzed by Western Blot. The intensity of the LYPLAL1 signal was normalized to that of HSP90, the loading control. Quantification is shown on the right; n=8 for veh and 7 for 12. n represents individual mice (body weights and Western blot) or cages (food intake). Error bars represent mean ± s.e.m. Representative results from two independent experiments; similar results were obtained in both experiments. Uncropped blots for b are shown in Supplementary Fig. 6